[Analysis the relationship of HBV BCP A1762T/G1764A double mutation with HBV related acute on chronic liver failure]

Related Experiment Video

Updated: Jun 5, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Tao Yan1, Ke Li, Hai-Bin Su

  • 1Liver Failure Treatment and Research Center, 302 Hospital, Beijing 100039, China.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology
|December 29, 2010
PubMed

Insights

The HBV BCP A1762T/G1764A double mutation is linked to the progression of Hepatitis B Virus (HBV) related liver diseases. However, this mutation is not specific to acute on chronic liver failure (ACLF) patients.

Area of Science:

  • Hepatology
  • Virology
  • Genetics

Context:

  • Hepatitis B Virus (HBV) infection is a global health concern.
  • The precore/core promoter (BCP) region of the HBV genome is a site of frequent mutations.
  • The A1762T/G1764A double mutation in the HBV BCP region has been associated with disease progression.

Purpose:

  • To investigate the association between the HBV BCP A1762T/G1764A double mutation and acute on chronic liver failure (ACLF).

Summary:

  • A study analyzed 166 patients with chronic HBV infection, including those with chronic hepatitis B (CHB), liver cirrhosis (LC), ACLF, and hepatocellular carcinoma (HCC).
  • The A1762T/G1764A double mutation was detected in 40.0% of CHB, 84.4% of LC, 73.5% of ACLF, and 92.6% of HCC patients.
  • No significant difference in mutation rates was found between ACLF patients and those with CHB or LC, nor between HBeAg-positive and negative patients. HBV DNA levels were similar between patients with and without the mutation.

Impact:

  • The HBV BCP A1762T/G1764A double mutation is closely related to the progression of HBV-related liver diseases.
  • This mutation is not a specific marker for ACLF.
  • The findings suggest that the mutation's presence does not significantly alter HBV DNA levels or HBeAg status.
Abstract

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...